Morgan Stanley upgraded Fisher & Paykel Healthcare to Overweight from Equal Weight with a price target of NZ$38.90, up from NZ$36.70. The share price has declined by about 4% following the FY25 result, which the firm sees as reflecting weaker than expected FY26 guidance, but it adds that it sees F&P offering attractive medium-long term EPS growth.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Reports Strong Earnings Growth
- Fisher & Paykel Healthcare upgraded to Buy from Hold at Jefferies
- Fisher & Paykel Healthcare downgraded to Underperform at RBC Capital
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution